TheStreet reaffirmed their positive rating on shares of Gilead Sciences (NASDAQ:GILD) in a report issued on Tuesday, Analyst Ratings Net reports.
“Gilead (GILD) has been reiterated by TheStreet Ratings as a buy with a ratings score of A-. The company’s strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.,” TheStreet’s analyst wrote.
Other equities research analysts have also recently issued reports about the stock. Analysts at Barclays set a $90.00 price target on shares of Gilead Sciences in a research note to investors on Tuesday. Separately, analysts at Bank of America Corp. raised their price target on shares of Gilead Sciences from $96.00 to $107.00 in a research note to investors on Friday, November 22nd. Finally, analysts at UBS AG reiterated a buy rating on shares of Gilead Sciences in a research note to investors on Friday, November 22nd. They now have a $107.00 price target on the stock, up previously from $96.00. Three equities research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $79.00.
Shares of Gilead Sciences (NASDAQ:GILD) traded up 0.40% on Tuesday, hitting $74.67. 3,639,574 shares of the company’s stock traded hands. Gilead Sciences has a one year low of $35.68 and a one year high of $75.43. The stock has a 50-day moving average of $68.20 and a 200-day moving average of $60.40. The company has a market cap of $114.5 billion and a price-to-earnings ratio of 40.93.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.52 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.48 by $0.04. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the previous year, the company posted $1.00 earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. Analysts expect that Gilead Sciences will post $2.00 EPS for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.